Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.2.1.1 (
ACS
)
78,556
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The plasmon resonant wavelength for a pair of gold nanoparticles, or gold nanodimer, increases inversely with the gap distance between the two nanoparticles. Taking advantage of this property, we performed nanoscale measurements of DNA conformation changes induced by transcription factor binding. Gold nanoparticles were bridged by double-stranded
DC5
DNA that included binding sequences for the transcription factors SOX2 and PAX6, which interact on the
DC5
enhancer sequence and activate transcription. The gold nanodimers bound by SOX2 shifted the plasmon resonant wavelength from 586.8 to 604.1 nm, indicating that SOX2 binding induces DNA bending. When the SOX2 formed a ternary complex with PAX6 on
DC5
, the plasmon resonant wavelength showed a further shift to 611.6 nm, indicating additional bending in the
DC5
sequence. Furthermore, we investigated DNA conformation changes induced by SOX2 and PAX6 on the
DC5
-con sequence, which is a consensus sequence of
DC5
for the PAX6 binding region that strengthens the PAX6 binding but at the same time disrupts SOX2-PAX6-dependent transcriptional activation. When the PAX6 binding sequence in
DC5
was altered to
DC5
-con, the plasmon resonant wavelength shifted much less to 606.5 nm, which is more comparable to the 603.9 nm by SOX2 alone. These results demonstrate that SOX2-PAX6 cobinding induces a large conformation change in
DC5
DNA.
ACS
Nano 2013 Dec 23
PMID:Nano-analysis of DNA conformation changes induced by transcription factor complex binding using plasmonic nanodimers. 2419 75